Abstract 【Objective】To investigate the predictive value of systemic immune-inflammatory index(SII) for no-reflow after percutaneous coronary intervention(PCI) in patients with acute ST segment elevation myocardial infarction(STEMI). 【Methods】The clinical data of 208 STEMI patients who underwent PCI in our hospital from January 2016 to April 2020 were retrospectively analyzed. According to whether no-reflow occurred after PCI, they were divided into normal reflow group and no-reflow group. The general clinical data of the two groups were compared. Cox multivariate regression analysis was used to analyze the risk factors of no-reflow. Receiver operating characteristic(ROC) curve was used to evaluate the predictive value of reperfusion time, HbA1c and SII for no-reflow. According to the cut-off value of SII to predict no-reflow, the patients were divided into SII low-level group and SII high-level group. The 3-year survival rates between normal reflow group and no-reflow group, SII low-level group and SII high-level group were compared. 【Results】The proportion of patients with TIMI grade > 2 and the proportion of diabetes mellitus in the no-reflow group were higher than those in the normal reflow group, and the levels of STB, DTB, CK-MB peak, HDL, postprandial blood glucose, FPG and SII in the no-reflow group were higher than those in the normal reflow group, with statistically significant differences(P<0.05). Cox multivariate regression analysis showed that STB, DTB, HbA1c and SII were the relevant factors affecting no-reflow (P<0.05). ROC curve analysis showed that STB, DTB, HbA1c and SII had predictive value for no-reflow, but SII had higher predictive value for no-reflow than STB, DTB and HbA1c(Z= 3.965, 4.201, 4.062;P=0.018, 0.014, 0.021). The 3-year survival rate in the no-reflow group was 56.3%(27/48), which was lower than 80.6%(129/160) in the normal reflow group, and the difference was statistically significant(P<0.05). The 3-year survival rate in the SII high-level group was 30.8%(20/65), which was lower than 84.2%(80/95) in the SII low-level group, and the difference was statistically significant(P<0.05). 【Conclusion】 SII can predict the occurrence of no-reflow after PCI in patients with STEMI, and can affect the postoperative survival rate of patients.
ZHANG Lixia,DONG Jinli. Predictive Value of Systemic Immune-inflammatory Index for No-reflow after PCI in Patients with Acute ST Segment Elevation Myocardial Infarction[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 352-355.
[1] 峁存. 急性ST段抬高型心肌梗死不同心电图表现患者心肌损伤标志物及无复流风险观察[J].医学临床研究,2023,40(12):1912-1915. [2] KLONER R A,KING K S,HARRINGTON M G. No-reflow phenomenon in the heart and brain[J].Am J Physiol Heart Circ Physiol,2018,315(3):H550-H562. [3] NDREPEPA G,TIROCH K,FUSARO M,et al. 5-year prognostic value of no-refow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction[J].J Am Coll Cardiol,2010,55(21):2383-2389. [4] NICCOLI G, LANZA G A, SPAZIANI C, et al. Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction[J].Int J Cardiol,2007,117(3):306-311. [5] HUANG J, ZHANG Q, WANG R, et al. Systemic immune-inflammatory index predicts clinical outcomes for elderly patients with acute myocardial infarction receiving percutaneous coronary intervention[J].Med Sci Monit,2019,25:9690-9701. [6] STONE G W,PETERSON M A,LANSKY A J,et al. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction[J].J Am Coll Cardiol,2002,39(4):591-597. [7] NAIR RAJESH G,JAYAPRASAD N,MADHAVAN S,et al.Predictors and prognosis of no-reflow during primary percutaneous coronary intervention[J].Proc(Bayl Univ Med Cent),2018,32(1):30-33. [8] CIOFANI J L,ALLAHWALA U K,SCARSINI R,et al. No-reflow phenomenon in ST-segment elevation myocardial infarction:still the Achilles' heel of the interventionalis[J].Future Cardiol,2021,17(2):383-397. [9] SÜLEYMANOĞLU M,RENCÜZOĞULLARI I.,KARABAĞ Y,et al. The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention[J].Int J Cardiovasc Imaging,2020,36(5):789-796. [10] MAZHAR J,MASHICHARAN M,FARSHID A. Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction[J].Int J Cardiol Heart Vasc,2015,10:8-12. [11] ALLENCHERRIL J,JNEID H,ATAR D,et al. Pathophysiology,diagnosis,and management of the No-reflow phenomenon[J].Cardiovasc Drugs Ther,2019,33(5):589-597. [12] WENNER J B,WONG G C,CAIRNS J A,et al. Impact of patient-and system-level delays on reperfusion among patients with ST-elevation myocardial infarction[J].CJC Open,2020,2(3):94-103. [13] BESSONOV I S,KUZNETSOV V A,ZIRYANOV I P,et al. Impact of Diabetes Mellitus and blood glucose levels on the results of treatment of patients with ST-elevation myocardial infarction undergoing percutaneous coronary interventions[J].Kardiologiia,2019,59(3s):16-22. [14] PANTEA-ROŞAN L R, PANTEA V A, BUNGAU S, et al. No-reflow after PPCI-A predictor of short-term outcomes in STEMI patients[J].J Clin Med,2020,9(9):2956. [15] QUAN X Y, LIU X C, QIN X C, et al. The role of LR-TIMAP/PP1c complex in the occurrence and development of no-reflow[J].EBioMedicine,2021,65:103251.
2024, Vol. 41 
